deoxycytidine and Carcinoma, Hepatocellular

deoxycytidine has been researched along with Carcinoma, Hepatocellular in 151 studies

Research

Studies (151)

Timeframe	Studies, this research(%)	All Research%
pre-1990	6 (3.97)	18.7374
1990's	2 (1.32)	18.2507
2000's	58 (38.41)	29.6817
2010's	79 (52.32)	24.3611
2020's	6 (3.97)	2.80

Authors

Authors	Studies
Chen, X; Fang, D; Guan, J; He, X; Shi, ZW; Wang, H; Wang, X	1
Bai, C; Fan, H; Ji, Y; Wang, Z; Yang, M; Yang, W	1
Guo, Y; Li, X; Liu, W; Liu, X; Shen, L; Sun, X; Wang, J; Yang, X; Yao, L; Yuan, J; Zhou, X	1
Nazari, M; Rosenblum, JS; Trumbo, S	1
Chen, X; Cui, SH; Ding, JS; Qian, HG; Qiu, C; Sun, J; Wang, CH; Wang, H; Wang, JC; Yan, Y; Zhang, HT; Zhang, Q	1
Al-Dhubiab, BE; Attimarad, M; Chavda, V; Jacob, S; Morsy, MA; Nair, AB; Patel, SS; Patel, V; Shah, J; Shinu, P; Sreeharsha, N; Venugopala, KN	1
Gong, JH; Liu, XJ; Miao, QF; Wang, RH; Wang, YX; Yang, SQ; Zhang, MR; Zhen, YS; Zheng, YB	1
Gao, LF; Han, J; Li, XL; Liu, QY; Liu, ZJ; Wang, XH; Xu, W	1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z	1
Anani, M; Attia, F; Elazab, M; Fathy, S; Hassan, A; Ibrahim, G	1
Cao, S; Stephenson, AA; Suo, Z; Taggart, DJ; Vyavahare, VP	1
Andronescu, E; Boldeiu, A; Grumezescu, AM; Mogoantă, L; Mogoșanu, GD; Popescu, RC; Radu, M; Savu, D; Temelie, M; Truşcă, R; Vasile, BȘ	1
Bansal, P; Baron, AD; Bedrick, E; Boumber, Y; Du, R; Fekrazad, MH; Lee, FC; Lee, SJ; Murad, W; Patt, YZ; Steinberg, K	1
Fan, L; Jin, X; Song, C; Wu, H; Zhang, Y; Zhao, S	1
Guo, Y; Hu, Y; Huang, Y; Liu, D; Lu, B; Wang, X; Zhu, Z	1
Bennouna, J; Caulet, M; Gournay, J; Hautefeuille, V; Lecomte, T; Matysiak-Budnik, T; Prieux-Klotz, C; Salimon, M; Tiako Meyo, M; Touchefeu, Y; Tougeron, D; Zaanan, A	1
Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H	1
Eng, JY; Soon, SY; Winnie Ling, HY	1
Asagi, A; Furuse, J; Horiguchi, S; Ikeda, M; Iwadou, S; Kobayashi, S; Kojima, Y; Mizuno, N; Moriguchi, M; Morizane, C; Otsuka, T; Shiba, S; Suzuki, E; Takada, R; Takahashi, H; Terashima, T; Tsuji, K; Ueno, M; Yamada, I; Yoshida, Y	1
Hasegawa, K; Inagaki, Y; Kamiya, M; Kaneko, J; Kokudo, N; Kokudo, T; Sato, M; Uno, SN; Urano, Y	1
Chen, J; Li, Z; Pan, Z; Yao, J; Yao, Z; Zhang, Y	1
Apisarnthanarax, S; Hallemeier, CL; Huguet, F; Jabbour, SK; Murphy, JD; Olsen, JR; Tait, D	1
Abdel-Aleem, JA; Abdelrahman, AA; Abdelrahman, SI; Gadalla, HH; Lyle, LT; Masters, AR; Park, J; Tamam, H; Yeo, Y	1
Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M	1
Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ	1
Bukh, J; Gottwein, JM; Jensen, SB; Li, YP; Pedersen, J; Ramirez, S	1
Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL	1
Chen, C; Chen, S; Chen, Y; Hou, X; Hou, Y; Miele, L; Sarkar, FH; Wang, R; Wang, Z; Wu, Q; Yang, Q; Yang, Y	1
Ashley, CE; Brinker, CJ; Brocato, TA; Butner, JD; Carnes, EC; Cristini, V; Koay, EJ; Pascal, J; Wang, Z	1
Agostini, V; Andreone, P; Biasco, G; Bolondi, L; Brandi, G; Cucchetti, A; de Rosa, F; di Girolamo, S; Golfieri, R; Gramenzi, A; Pinna, AD; Sama, C; Serra, C; Trevisani, F	1
Ahmad, S; Khattak, J; Murad, S; Naqi, N	1
Han, Z; Peng, Z; Sun, H; Wu, J	1
Cisneros, BT; Corr, SJ; Curley, SA; Kaluarachchi, WD; Phounsavath, S; Raoof, M; Wilson, LJ; Zhu, C	1
Li, J; Li, T; Li, Z; Liu, F; Sun, X; Xiu, P; Xu, Z; Zou, F	1
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO	1
Boige, V; Bouattour, M; Ducreux, M; Faivre, S; Fartoux, L; Fayard, F; Malka, D; Patrikidou, A; Regnault, H; Sinapi, I	1
Srimuninnimit, V; Sriuranpong, V; Suwanvecho, S	1
Cisneros, BT; Corr, SJ; Curley, SA; Liu, H; Raoof, M; Wilson, LJ; Zhu, C	1
Guo, B; Liu, J; Song, L; Wu, J; Zhao, DY	1
Wang, GS	1
Ke, Y; Li, XN; Ruan, J; Yi, SY; Zhao, L	1
He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB	1
Li, K; Liu, Y; Ma, N; Qiao, L; Wang, F; Wang, J; Xu, S; Yue, H	1
Chen, C; Chen, S; Hou, Y; Li, Y; Wang, R; Wang, X; Wang, Z; Wu, Q; Yang, Q; Yang, Y	1
Dong, J; Liu, J; Xu, K; Yu, G	1
Fan, M; Li, Z; Liang, X; Shi, B; Wang, H; Yang, D	1
Clément, B; Coulouarn, C; Crouzet, L; Edeline, J; Garin, E; Lepareur, N; Pracht, M	1
Li, Y; Liu, J; Liu, Y; Qin, S; Su, F; Wang, R; Wang, Z; Wu, Q; Yang, Y; Zhao, F	1
Chapuy, CI; Kozyreva, ON; Sahai, I; Sharma, R; Zhu, AX	1
Du, L; Jin, Y; Lei, Y; Wang, S; Zhang, B	1
Li, Y; Liu, J; Liu, Y; Ou, W; Su, F; Wang, R; Wang, X; Wu, Q; Zheng, J	1
Gong, XL; Qin, SK	1
Devulapally, R; Foygel, K; Paulmurugan, R; Sekar, TV; Willmann, JK	1
Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J	1
Chia, WK; Choo, SP; Foo, KF; Hee, SW; Koo, WH; Ong, S; Poon, DY; Tan, CK; Tay, MH; Toh, HC	1
Matsumoto, K; Murawaki, Y; Nagahara, T; Okano, J	1
Doval, DC; Jena, A; Pande, SB; Pavithran, K; Sharma, JB; Vaid, AK	1
Haviland, D; Kemeny, N; Patel, D; Tse, AN; Wu, N	1
Finn, RS; Zhu, AX	1
Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY	1
Al-Osaimi, AM; Angle, JF; Argo, C; Berg, C; Caldwell, S; Hagspiel, KD; McIntosh, A; Northup, P; Rich, TA; Weiss, G	1
Cheng, YC; Chu, E; Foo, A; Jiang, Z; Liu, SH; Rose, M; Saif, MW; So, S; Su, T; Yen, Y	1
Wang, ZY	1
Adham, M; Boschetti, G; Cassier, P; Dumortier, J; Hervieu, V; Lombard-Bohas, C; Scoazec, JY; Walter, T	1
Chao, TY; Chen, PJ; Cheng, AL; Epstein, RJ; Hsiao, LT; Hsu, C; Hsu, CH; Lin, ZZ; Toh, HC; Yang, TS	1
Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY	1
Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z	1
Bureau, C; Buscail, L; Cordelier, P; Diab, T; Dusetti, N; Gayet, O; Hanoun, N; Selves, J; Torrisani, J; Vinel, JP	1
Cillo, U; Donach, M; Farina, M; Farinati, F; Lombardi, G; Pastorelli, D; Vitale, A; Zanus, G; Zovato, S; Zustovich, F	1
Büchler, MW; Franz, C; Hoffmann, K; Mohr, E; Schemmer, P; Serba, S; Xiao, Z	1
Caparro, M; Giantonio, B; Haller, DG; Mykulowycz, K; O'Dwyer, PJ; Olthoff, K; Reddy, R; Rosen, M; Shaked, A; Sohal, D; Soulen, MC; Sun, W; Teitelbaum, UR	1
Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC	1
Akladios, CY; Aprahamian, M; Balboni, G; Bour, G; Marescaux, J; Mutter, D	1
Jiang, T; Kambadakone, A; Kulkarni, NM; Sahani, DV; Zhu, AX	1
Alberts, SR; Camoriano, JK; Enger, JR; Farr, GH; Johnson, DB; Kim, GP; Morlan, BW; Reid, JM; Seay, TE	1
Belghiti, J; Botti, M; Boussaha, T; Dubreuil, O; Housset, M; Landi, B; Rougier, P; Taieb, J; Trouilloud, I; Williet, N	1
Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W	1
Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C	1
Katano, M; Kiyota, A; Koya, N; Morisaki, T; Nagamatsu, I; Ogino, T; Onishi, H; Tanaka, H; Umebayashi, M	1
Fukunaga, K; Hirata, Y; Iida, H; Kakuno, A; Morita, M; Murata, S; Nishigami, T; Tamura, M; Tani, S; Yamanaka, N	1
Brodsky, EM; Elpiner, AK; Hazzah, TN; Post, GS	1
Chang, YJ; Hung, CS; Kuo, LJ; Li, LT; Liew, PL; Lin, FY; Lin, SF; Liu, DZ; Liu, HH; Su, HY; Wei, PL	1
Engels, KS; Farshid, P; Gruber-Rouh, T; Lehnert, T; Naguib, NN; Nour-Eldin, NE; Vogl, TJ	1
Burt, AD; Dasari, BV; Kelly, PJ; Loughrey, MB; Spence, R; Taylor, M	1
Boudou-Rouquette, P; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mallet, V; Mir, O; Pol, S; Ropert, S; Sogni, P	1
Du, L; Gao, C; Jin, Y; Lian, Y; Su, C; Wang, S	1
Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY	1
Li, G; Li, W; Qu, X; Sun, C; Xue, X; Zhao, C	1
Aldea, M; Berindan-Neagoe, I; Cristea, V; Dudea, M; Florea, A; Irimie, A; Kacso, G; Mosteanu, O; Orza, A; Pall, E; Petrushev, B; Soritau, O; Susman, S; Tomuleasa, C	1
Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J	1
Boige, V; Bonnetain, F; Cattan, S; Dabakuyo, TS; Dubreuil, O; Fartoux, L; Hebbar, M; Mansourbakht, T; Rosmorduc, O; Taïeb, J; Williet, N; Zaanan, A	1
Boudou-Rouquette, P; Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Goldwasser, F; Mir, O; Perkins, G	1
Chan, PC; Chou, LS; Ho, CH; Lin, MH; Lin, WJ; Liu, RS; Shen, CC; Wang, HE; Wu, CY	1
Jang, JW; Kay, CS; Kim, JY; Kim, KJ; Kwon, JH; Yoo, EJ	1
Chen, WC; Hsu, YC; Lee, JC; Lin, CK; Lin, YT; Tseng, CK; Wu, YH	1
Clark, JW; Earle, CC; Fuchs, CS; Kim, H; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, KE; Vincitore, M	1
Chen, JS; Fung, MC; Hsieh, RK; Wang, CH; Yang, TS	1
Chao, Y; Hung, MC; Lee, SD; Lee, WP; Tai, DI; Tsai, SL; Yeh, CT	1
Chen, Z; Guan, Z; Kim, TW; Kim, WS; Lehnert, M; Maoleekoonpairoj, S; Ratanatharathorn, V; Reece, WH; Wang, Y	1
Boige, V; Boleslawski, E; Bonyhay, L; de Baere, T; Delgado, MA; Ducreux, M; Golli, L; Hannoun, L; Mansourbakht, T; Poynard, T; Taïeb, J; Tigaud, JM	1
Fan, J; Ji, Y; Li, XM; Liu, YK; Shi, YH; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Ye, SL; Zhou, J	1
Altmann, A; Eskerski, H; Haberkorn, U; Jiang, S; Kleinschmidt, J; Mier, W; Schönsiegel, F; Sieger, S	1
De Gelder, V; De Ridder, L; Dierckx, RA; Lambert, B; Slegers, G; Thierens, H	1
Fan, J; Liu, YK; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Xue, Q; Ye, SL; Zhao, Y; Zhou, J	1
Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J; Sagir, A	1
Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA	1
Chen, LH; Lü, YY; Yang, J	1
Blankenberg, FG; Kuge, Y; Sato, M; Strauss, HW; Tait, JF; Takei, T; Tamaki, N; Zhao, S	1
Chen, T; Chu, ZH; Liu, JP; Ou, QJ; Wang, J; Zhao, HY	1
Boyer, JC; Ciccolini, J; Dahan, L; Dales, JP; Durand, A; Evrard, A; Lacarelle, B; Mercier, C; Milano, G; Richard, K; Seitz, JF	1
Bai, LY; Chen, PM; Poh, SB	1
Bang, SM; Cho, EK; Han, SH; Kim, JH; Kim, SS; Kwon, OS; Kwon, SY; Lee, JH; Lee, JN; Lee, Y; Park, SH; Park, YH; Shin, DB	1
Lim, ST; Ong, S; Quek, R	1
Diasio, R; Saif, MW	1
Bhargava, P; Blaszkowsky, LS; Clark, JW; Enzinger, PC; Hale, KE; Horgan, K; Muzikansky, A; Ryan, DP; Sheehan, S; Stuart, K; Zhu, AX	1
Bearz, A; Berretta, M; Di Benedetto, F; Lleshi, A; Spina, M; Tirelli, U	1
A-Hon, K; Kamiyama, Y; Komiyama, Y; Satoi, S; Takahashi, H; Takahashi, K; Takai, S; Terakawa, N; Yanagimoto, H	1
Artioli, G; Binato, S; Cartei, G; Ceravolo, R; Cillo, U; Cingarlini, S; Farinati, F; Marchese, F; Mattiazzi, M; Pastorelli, D; Salmaso, F; Sanavio, C; Zanus, G; Zovato, S; Zustovich, F	1
de Gelder, V; De Ridder, L; De Vos, F; Lambert, B; Slegers, G; Thierens, H; Van de Wiele, C	1
Asnacios, A; Boige, V; Bonyhay, L; de Baere, T; Ducreux, M; Hannoun, L; Louafi, S; Mansourbakht, T; Poynard, T; Taïeb, J	1
Funk, A; Gaertner, K; Krahn, I; Lin, L; Matthes, E; Sirma, H; von Janta-Lipinski, M; Will, H	1
Alberts, SR; Chari, ST; Gores, GJ; Kendrick, ML; Kim, GP; Martenson, JA; Roberts, LR; Rosen, CB	1
Bussom, S; Cheng, YC; Lam, W; Leung, CH	1
Chen, Q; Chen, TG; Hao, MZ; Lin, HL; Wu, H; Yu, WC	1
André, T; Blanchard, P; Huguet, F	1
Blanc, JF; Boige, V; Bouché, O; Dahan, L; Ducreux, M; Dupouy, N; Jouve, JL; Pignon, JP; Raoul, JL	1
Saif, MW; Tejani, MA	1
Ansiaux, R; Beghein, N; Cron, GO; Feron, O; Gallez, B; Martinive, P	1
Chou, SJ; Chu, CH; Chu, HC; Hsieh, CB; Shih, ML; Yao, NS; Yu, JC	1
Huang, F; Liang, ZY; Xiong, ZP; Zhang, YD	1
Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S	1
Holalkere, NS; Horgan, K; Muzikansky, A; Sahani, DV; Zhu, AX	1
Han, CJ	1
Artru, P; Asnacios, A; Fartoux, L; Hebbar, M; Louafi S, S; Mansoubakht, T; Poynard, T; Romano, O; Rosmorduc, O; Taieb, J; Tesmoingt, C	1
Kim, CM; Lee, WJ; Nam, BH; Park, JW; Shim, JH	1
Aikata, H; Chayama, K; Ito, K; Kawaoka, T; Miki, D; Saneto, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K	1
Ayoub, WS; Keeffe, EB	1
Geisen, FH; Graziadei, I; Kelly, T; Konwalinka, G; Schirmer, M; Vogel, W	1
Brooks, JD; De Marzo, AM; Freije, D; Hirohashi, S; Isaacs, WB; Kanai, Y; Lin, X; Nelson, WG; Rashid, A; Tchou, JC	1
Chen, JS; Lin, YC; Wang, CH; Wang, HM; Yang, TS	1
Fan, J; Tang, Z; Zhou, J	1
Fiebiger, W; Kornek, GV; Raderer, M; Scheithauer, W; Schüll, B; Ulrich-Pur, H	1
Aguayo, A; Patt, YZ	1
Bridges, EG; Bryant, ML; Cretton-Scott, E; Dukhan, D; Faraj, A; Gosselin, G; Hernandez-Santiago, B; Imbach, JL; Pierra, C; Placidi, L; Rodriguez-Orengo, J; Sommadossi, JP	1
Hilliard, JK; Sneider, TW	1
Marz, R; Plagemann, PG; Wohlhueter, RM	1
Acs, G; Banerjee, R; Jeffrey, AM; Price, PM	1
Bevers, MM; van Rijn, H; van Wijk, R; Wicks, WD	1
Bevers, MM; van Rijn, J; van Wijk, R; Wicks, WD	1
Sneider, TW	1
Goodman, JI	1

Reviews

14 review(s) available for deoxycytidine and Carcinoma, Hepatocellular

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Progress in systemic therapy of advanced hepatocellular carcinoma. World journal of gastroenterology, 2016, Aug-07, Volume: 22, Issue:29 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Fluorouracil; Humans; Immunotherapy; Leucovorin; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Organoplatinum Compounds; Transforming Growth Factor beta	2016
Treatment of chronic hepatitis B infection: an update of Swedish recommendations. Scandinavian journal of infectious diseases, 2008, Volume: 40, Issue:6-7 Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Transplantation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Sweden; Tenofovir	2008
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert review of anticancer therapy, 2009, Volume: 9, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A	2009
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib	2009
Primary hepatocellular carcinoma of the pancreas: a case report and review of the heterogeneous group of pancreatic hepatoid carcinomas. Histopathology, 2012, Volume: 60, Issue:6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms	2012
[New approaches in the treatment of hepatitis B]. Deutsche medizinische Wochenschrift (1946), 2004, May-21, Volume: 129, Issue:21 Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Emtricitabine; Famciclovir; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Organophosphorus Compounds; Polyethylene Glycols; Prodrugs; Prognosis; Recombinant Proteins; Tenofovir; Zalcitabine	2004
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Treatment Outcome	2006
Treatment options for hepatobiliary and pancreatic cancer. Mayo Clinic proceedings, 2007, Volume: 82, Issue:5 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Ethanol; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Analysis	2007
[Gemcitabine and digestive carcinomas]. Bulletin du cancer, 2007, Volume: 94 Spec No Actualites Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Digestive System Neoplasms; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Stomach Neoplasms	2007
Safety of capecitabine use in patients with liver dysfunction. Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:9 Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms	2007
[Recent developments in systemic chemotherapy for hepatocellular carcinoma]. The Korean journal of hepatology, 2008, Volume: 14, Issue:1 Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Capecitabine; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Immunologic Factors; Liver Neoplasms; Tegafur	2008
Review article: current antiviral therapy of chronic hepatitis B. Alimentary pharmacology & therapeutics, 2008, Volume: 28, Issue:2 Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication	2008
Nonsurgical treatment of hepatocellular carcinoma. Seminars in oncology, 2001, Volume: 28, Issue:5 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cryosurgery; Deoxycytidine; Drug Combinations; Ethanol; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Intra-Arterial; Injections, Intralesional; Interferons; Liver Cirrhosis; Liver Neoplasms; Octreotide; Radiopharmaceuticals; Radiotherapy Dosage; Tamoxifen; Tegafur; Uracil	2001

Trials

32 trial(s) available for deoxycytidine and Carcinoma, Hepatocellular

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. Cancer medicine, 2017, Volume: 6, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis; Treatment Outcome	2017
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecologic oncology, 2018, Volume: 148, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome	2018
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:3 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib	2013
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. The oncologist, 2013, Volume: 18, Issue:12 Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome	2013
Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study. Hematology/oncology and stem cell therapy, 2014, Volume: 7, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Demography; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome	2014
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. Investigational new drugs, 2014, Volume: 32, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Sorafenib	2014
Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study. Asia-Pacific journal of clinical oncology, 2014, Volume: 10, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib	2014
Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial. Oncology, 2015, Volume: 89, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Hepatic Artery; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Single-Blind Method; Tomography, X-Ray Computed; Treatment Outcome	2015
Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma. Annals of the Academy of Medicine, Singapore, 2008, Volume: 37, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome	2008
A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:5 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusion Pumps, Implantable; Liver; Liver Neoplasms; Male; Middle Aged; Treatment Outcome	2009
Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer research, 2009, Volume: 29, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Quality of Life; Survival Rate	2009
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. British journal of cancer, 2010, Mar-16, Volume: 102, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Treatment Outcome; Young Adult	2010
Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Annals of surgical oncology, 2010, Volume: 17, Issue:12 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Care; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult	2010
Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer, 2011, Jan-01, Volume: 117, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols	2011
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer, 2011, Jul-15, Volume: 117, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin	2011
Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Investigative radiology, 2012, Volume: 47, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Deoxycytidine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Perfusion Imaging; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome	2012
Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. American journal of clinical oncology, 2012, Volume: 35, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome	2012
Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Hepatocellular; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Analysis; Taiwan; Treatment Outcome	2002
Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. British journal of cancer, 2003, Nov-17, Volume: 89, Issue:10 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Treatment Outcome	2003
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. American journal of clinical oncology, 2005, Volume: 28, Issue:6 Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Doxorubicin; Fatigue; Female; Fluorouracil; Gemcitabine; Hepatitis B, Chronic; Humans; Liposomes; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Proteins; Paresthesia; Polyethylene Glycols; Salvage Therapy; Survival Analysis; Treatment Outcome	2005
Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC cancer, 2006, Jan-05, Volume: 6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Doxorubicin; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Treatment Outcome	2006
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Apr-20, Volume: 24, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Vascular Endothelial Growth Factor A	2006
Clinical monitoring of innate cellular immunity of monocytes/macrophages by tumor necrosis factor alpha productivity in whole blood stimulated by lipopolysaccharide in patients with pancreatic cancer. Pancreas, 2006, Volume: 33, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunity, Cellular; Lipopolysaccharides; Liver Neoplasms; Macrophages; Male; Middle Aged; Monocytes; Pancreatectomy; Pancreatic Neoplasms; Survival Analysis; Tumor Necrosis Factor-alpha	2006
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Treatment Outcome	2006
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer, 2007, Apr-01, Volume: 109, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome	2007
[Efficacy of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma: a controlled randomized trial]. Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:8 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Deoxycytidine; Exanthema; Female; Floxuridine; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Thalidomide; Young Adult	2007
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. British journal of cancer, 2007, Oct-08, Volume: 97, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prognosis; Survival Rate; Treatment Outcome	2007
Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2008, Volume: 34, Issue:8 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Treatment Outcome	2008
Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. The oncologist, 2008, Volume: 13, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prognosis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2008
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer, 2008, Jun-15, Volume: 112, Issue:12 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cetuximab; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin	2008
Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer, 2000, Aug-15, Volume: 89, Issue:4 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome	2000

Other Studies

107 other study(ies) available for deoxycytidine and Carcinoma, Hepatocellular

Article	Year
Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model. Clinics and research in hepatology and gastroenterology, 2022, Volume: 46, Issue:4 Topics: Animals; B7-H1 Antigen; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Mice; Neoplasm Recurrence, Local; Programmed Cell Death 1 Receptor; Transforming Growth Factor beta; Tumor Microenvironment	2022
Synergistic Effect of Baculovirus-Mediated Endostatin and Angiostatin Combined with Gemcitabine in Hepatocellular Carcinoma. Biological & pharmaceutical bulletin, 2022, Mar-01, Volume: 45, Issue:3 Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Baculoviridae; Carcinoma, Hepatocellular; Deoxycytidine; Endostatins; Gemcitabine; Humans; Liver Neoplasms; Mice; Mice, Nude	2022
Combined Aberrant Expression of NDRG2 and LDHA Predicts Hepatocellular Carcinoma Prognosis and Mediates the Anti-tumor Effect of Gemcitabine. International journal of biological sciences, 2019, Volume: 15, Issue:9 Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Lactate Dehydrogenase 5; Liver Neoplasms; Male; Mice; Middle Aged; Prognosis; Real-Time Polymerase Chain Reaction; Tumor Suppressor Proteins	2019
Hepatitis B-associated hepatocellular carcinoma in a young Haitian man: a review of screening guidelines. BMJ case reports, 2019, Oct-10, Volume: 12, Issue:10 Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Deoxycytidine; Diagnosis, Differential; Fatal Outcome; Gemcitabine; Haiti; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Mass Screening; Oxaliplatin; Practice Guidelines as Topic; Sorafenib; Tomography, X-Ray Computed	2019
Encapsulated microRNA by gemcitabine prodrug for cancer treatment. Journal of controlled release : official journal of the Controlled Release Society, 2019, 12-28, Volume: 316 Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Nanoparticles; Oleic Acid; Particle Size; Prodrugs; Xenograft Model Antitumor Assays	2019
Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma. Molecules (Basel, Switzerland), 2019, Dec-13, Volume: 24, Issue:24 Topics: 2-Acetylaminofluorene; Animals; Antimetabolites, Antineoplastic; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Chitosan; Deoxycytidine; Gemcitabine; Liver Neoplasms; Male; Nanoparticles; Rats; Xenograft Model Antitumor Assays	2019
Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling. Cancer biology & therapy, 2020, 04-02, Volume: 21, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Deoxycytidine; Dexamethasone; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptors, Glucocorticoid; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2020
Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells. Anti-cancer drugs, 2020, Volume: 31, Issue:7 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Pancreatic Neoplasms; Quercetin; Tumor Suppressor Protein p53	2020
Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma. Journal of clinical laboratory analysis, 2020, Volume: 34, Issue:11 Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cross-Sectional Studies; Deoxycytidine; Deoxycytidine Kinase; Egypt; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Real-Time Polymerase Chain Reaction; Treatment Outcome	2020
Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma. European journal of medicinal chemistry, 2021, Mar-05, Volume: 213 Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Gemcitabine; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Microbial Sensitivity Tests; Molecular Structure; Prodrugs; Structure-Activity Relationship; Virus Replication	2021
Fabrication and Cytotoxicity of Gemcitabine-Functionalized Magnetite Nanoparticles. Molecules (Basel, Switzerland), 2017, Jun-28, Volume: 22, Issue:7 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erythrocytes; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Magnetite Nanoparticles; Nanotechnology	2017
Synergistic chemo-photodynamic therapy by "big & small combo nanoparticles" sequential release system. Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Liberation; Female; Gemcitabine; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Photochemotherapy; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2018
Mycoplasma-associated multidrug resistance of hepatocarcinoma cells requires the interaction of P37 and Annexin A2. PloS one, 2017, Volume: 12, Issue:10 Topics: Adaptor Proteins, Signal Transducing; Annexin A2; Anti-Bacterial Agents; Antineoplastic Agents; Azithromycin; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoroquinolones; Gemcitabine; Humans; Liver Neoplasms; Mitoxantrone; Moxifloxacin; Mycoplasma hyorhinis; Protein Binding; Real-Time Polymerase Chain Reaction	2017
Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. British journal of cancer, 2018, 02-06, Volume: 118, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bilirubin; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Progression; Female; France; Gemcitabine; Hepatitis B Antibodies; Hepatitis C Antibodies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms, Complex and Mixed; Oxaliplatin; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate	2018
Curative lung metastectomy and complete pathological response after neo-adjuvant GEMOX chemotherapy for relapse fibrolamellar hepatocellular carcinoma. The Medical journal of Malaysia, 2018, Volume: 73, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Female; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Tomography, X-Ray Computed	2018
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer science, 2018, Volume: 109, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Young Adult	2018
A novel liver-specific fluorescent anti-cancer drug delivery system using indocyanine green. Scientific reports, 2019, 02-28, Volume: 9, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Fluorescent Dyes; Gemcitabine; Hepatocytes; Human Umbilical Vein Endothelial Cells; Humans; Indocyanine Green; Injections, Intravenous; Liver; Liver Neoplasms; Male; Mice; Microscopy, Fluorescence; Xenograft Model Antitumor Assays	2019
Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy. Medical science monitor basic research, 2019, Apr-08, Volume: 25 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Docetaxel; Epirubicin; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Polyethyleneimine; Viral Proteins	2019
Gastrointestinal Cancers: Management of Rectal, Hepatocellular, Pancreatic, and Esophageal Cancers. International journal of radiation oncology, biology, physics, 2019, 05-01, Volume: 104, Issue:1 Topics: Carcinoma, Hepatocellular; Deoxycytidine; Esophageal Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies	2019
Development of Liposomal Gemcitabine with High Drug Loading Capacity. Molecular pharmaceutics, 2019, 07-01, Volume: 16, Issue:7 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Therapy, Combination; Gemcitabine; Humans; Liposomes; Liver Neoplasms; Male; Mice; Mice, Nude; Tumor Burden; Xenograft Model Antitumor Assays	2019
Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. World journal of gastroenterology, 2013, Jul-28, Volume: 19, Issue:28 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Young Adult	2013
Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:2 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Chimera; Deoxycytidine; Genotype; Hepacivirus; Humans; Lead; Liver Neoplasms; Mutation; Peptide Hydrolases; Sofosbuvir; Transfection; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. Journal of clinical gastroenterology, 2014, Volume: 48, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Signal Transduction; Sorafenib; Time Factors; Treatment Outcome	2014
Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget, 2013, Volume: 4, Issue:11 Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Growth Processes; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Lymphokines; Phenotype; Platelet-Derived Growth Factor; Signal Transduction; Transfection	2013
Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response. ACS nano, 2013, Dec-23, Volume: 7, Issue:12 Topics: Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Liposomes; Liver Neoplasms; Models, Theoretical; Nanomedicine; Nanoparticles	2013
A single center experience: post-transplantation adjuvant chemotherapy impacts the prognosis of hepatocellular carcinoma patients. Chinese medical journal, 2014, Volume: 127, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Liver Transplantation; Male	2014
Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma. Nanomedicine : nanotechnology, biology, and medicine, 2014, Volume: 10, Issue:6 Topics: Animals; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Gold; Humans; Hyperthermia, Induced; Liver; Liver Neoplasms; Metal Nanoparticles; Mice, Inbred BALB C; Nanoconjugates	2014
Downregulating sCLU enhances the sensitivity of hepatocellular carcinoma cells to gemcitabine by activating the intrinsic apoptosis pathway. Digestive diseases and sciences, 2014, Volume: 59, Issue:8 Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Proteins; Clusterin; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Nuclear Proteins	2014
Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Investigational new drugs, 2014, Volume: 32, Issue:5 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Tomography, X-Ray Computed; Treatment Outcome	2014
Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks. Journal of the National Cancer Institute, 2014, Volume: 106, Issue:8 Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Cycle; Cell Survival; Deoxycytidine; Disease Models, Animal; DNA Replication; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Exonucleases; Gemcitabine; Humans; Hyperthermia, Induced; Liver Neoplasms; Mice; Mice, SCID; MRE11 Homologue Protein; Neoplasms, Experimental; Radio Waves; Radiofrequency Therapy; Recombinational DNA Repair	2014
Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World journal of gastroenterology, 2014, Aug-21, Volume: 20, Issue:31 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Deoxycytidine; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome	2014
GEMOX as the best hope for combined hepatocellular carcinoma and cholangiocarcinoma? Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2014, Volume: 24, Issue:10 Topics: Carcinoma, Hepatocellular; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome	2014
Metronomic gemcitabine targeted tumor vascular microenvironment decreases the population of CD133(+) cells in hepatocarcinoma xenografts. Cancer biomarkers : section A of Disease markers, 2014, Volume: 14, Issue:6 Topics: AC133 Antigen; Angiogenesis Inhibitors; Animals; Antigens, CD; Carcinoma, Hepatocellular; Deoxycytidine; Endothelial Cells; Gemcitabine; Glycoproteins; Humans; Liver Neoplasms; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic; Peptides; Tumor Microenvironment; Xenograft Model Antitumor Assays	2014
First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. International journal of clinical oncology, 2015, Volume: 20, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Prospective Studies; Sorafenib	2015
The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells. Oncotarget, 2015, Mar-30, Volume: 6, Issue:9 Topics: Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Hep G2 Cells; Humans; Immunohistochemistry; Liver Neoplasms; Lymphokines; MicroRNAs; Molecular Sequence Data; Neoplasm Invasiveness; Nuclear Proteins; Platelet-Derived Growth Factor; Twist-Related Protein 1; Wound Healing	2015
Uncoupling protein 2 mediates resistance to gemcitabine-induced apoptosis in hepatocellular carcinoma cell lines. Bioscience reports, 2015, Jun-16, Volume: 35, Issue:4 Topics: Apoptosis; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Hep G2 Cells; Humans; Ion Channels; Liver Neoplasms; Mitochondrial Proteins; Neoplasm Proteins; Uncoupling Protein 2	2015
Chlorambucil gemcitabine conjugate nanomedicine for cancer therapy. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2015, Nov-15, Volume: 79 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Chlorambucil; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Nanoconjugates; Nanomedicine; Neoplasm Transplantation; Neoplasms	2015
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. Journal of vascular and interventional radiology : JVIR, 2015, Volume: 26, Issue:12 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Synergism; Gemcitabine; Humans; Niacinamide; Organoplatinum Compounds; Paclitaxel; Phenylurea Compounds; Pyridines; Radiation Tolerance; Radiopharmaceuticals; Sorafenib; Yttrium Radioisotopes	2015
MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells. Journal of experimental & clinical cancer research : CR, 2016, Jan-27, Volume: 35 Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Neoplasm Invasiveness; Smad4 Protein	2016
Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm. The oncologist, 2016, Volume: 21, Issue:4 Topics: Adult; Brain Diseases; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Hyperammonemia; Liver Neoplasms; Male; Organoplatinum Compounds; Ornithine Carbamoyltransferase Deficiency Disease; Oxaliplatin	2016
Long-circulating and liver-targeted nanoassemblies of cyclic phosphoryl N-dodecanoyl gemcitabine for the treatment of hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2016, Volume: 79 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Hydrogen-Ion Concentration; Injections, Intravenous; Liver; Liver Neoplasms; Male; Mice; Nanoparticles; Solutions; Tissue Distribution; Tumor Burden	2016
Nutlin-3 reverses the epithelial-mesenchymal transition in gemcitabine-resistant hepatocellular carcinoma cells. Oncology reports, 2016, Volume: 36, Issue:3 Topics: Apoptosis; Cadherins; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Imidazoles; Liver Neoplasms; Neoplasm Invasiveness; Piperazines; Smad2 Protein; Snail Family Transcription Factors; Tumor Suppressor Protein p53; Vimentin	2016
Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy. ACS applied materials & interfaces, 2016, Dec-14, Volume: 8, Issue:49 Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Lactic Acid; Liver Neoplasms; MicroRNAs; Nanoparticles; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer	2016
The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncology reports, 2008, Volume: 20, Issue:4 Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cholangiocarcinoma; Deoxycytidine; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Liver Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases	2008
Prometheus' spirit: quality survival in advanced hepatocellular carcinoma after gemcitabine and cisplatin-based chemotherapy. Singapore medical journal, 2008, Volume: 49, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quality of Life; Remission Induction; Treatment Outcome	2008
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Rate	2009
Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. Cancer, 2009, Nov-01, Volume: 115, Issue:21 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Radiotherapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Treatment Outcome	2009
Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy? European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:8 Topics: Adult; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib	2010
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. American journal of clinical oncology, 2011, Volume: 34, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Treatment Failure	2011
The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions. Journal of hepatology, 2010, Volume: 53, Issue:5 Topics: Alternative Splicing; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Down-Regulation; Gemcitabine; Hep G2 Cells; Humans; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; Liver Neoplasms; Protein Isoforms; Proto-Oncogene Proteins; Tumor Suppressor Protein p53	2010
Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma. Anticancer research, 2010, Volume: 30, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Survival Rate; Tumor Cells, Cultured	2010
Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. American journal of clinical oncology, 2012, Volume: 35, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Thalidomide	2012
[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats]. Bulletin du cancer, 2011, Volume: 98, Issue:2 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Deoxycytidine; Disease Models, Animal; Disease Progression; Doxorubicin; Drug Monitoring; Gemcitabine; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Rats; Rats, Inbred ACI; Sorafenib; Survival Analysis; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays	2011
Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. World journal of gastroenterology, 2011, May-07, Volume: 17, Issue:17 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Sorafenib	2011
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2011
Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. Hematology/oncology and stem cell therapy, 2011, Volume: 4, Issue:2 Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Capecitabine; Carcinoma, Hepatocellular; Cell Line; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorescent Dyes; Fluorouracil; Glycoproteins; Hep G2 Cells; Humans; Immunohistochemistry; Interferon-alpha; Liver Neoplasms; Oxides; Peptides; Rhodamine 123; Thy-1 Antigens	2011
Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system. Anticancer research, 2011, Volume: 31, Issue:7 Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Combined Modality Therapy; Cytotoxicity, Immunologic; Deoxycytidine; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class I; Humans; In Vitro Techniques; Interleukin-2; Liver Neoplasms; Monocytes, Activated Killer; Muromonab-CD3; NK Cell Lectin-Like Receptor Subfamily K; Recombinant Proteins	2011
[Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2011, Volume: 108, Issue:11 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carboplatin; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male	2011
Single-agent gemcitabine chemotherapy in dogs with hepatocellular carcinomas. Veterinary and comparative oncology, 2011, Volume: 9, Issue:4 Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Dog Diseases; Dogs; Female; Gemcitabine; Liver Neoplasms; Male; Survival Analysis; Treatment Outcome; Ultrasonography	2011
Survivin-mediated therapeutic efficacy of gemcitabine through glucose-regulated protein 78 in hepatocellular carcinoma. Annals of surgical oncology, 2012, Volume: 19, Issue:8 Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Flow Cytometry; Gemcitabine; Heat-Shock Proteins; Humans; In Situ Nick-End Labeling; Inhibitor of Apoptosis Proteins; Liver Neoplasms; RNA, Small Interfering; Survivin; Tumor Cells, Cultured	2012
Retrospective study on the use of different protocols for repeated transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma. Academic radiology, 2012, Volume: 19, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Liver Neoplasms; Male; Mitomycin; Prevalence; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome	2012
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib	2012
Self-assembled drug delivery systems. Part 6: in vitro/in vivo studies of anticancer N-octadecanoyl gemcitabine nanoassemblies. International journal of pharmaceutics, 2012, Jul-01, Volume: 430, Issue:1-2 Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemistry, Pharmaceutical; Cholesterol Esters; Deoxycytidine; Drug Delivery Systems; Female; Hep G2 Cells; Humans; Injections, Intravenous; Liver Neoplasms; Mice; Nanomedicine; Nanostructures; Particle Size; Polyethylene Glycols; Surface Properties; Technology, Pharmaceutical; Tissue Distribution; Tumor Burden	2012
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-15, Volume: 18, Issue:14 Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Serum; Sorafenib; Tegafur; Treatment Outcome	2012
Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine. Chemical biology & drug design, 2012, Volume: 80, Issue:3 Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Carcinoma, Hepatocellular; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Mice; Neoplasms; Prodrugs	2012
Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells. Journal of gastrointestinal and liver diseases : JGLD, 2012, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Capecitabine; Carcinoma, Hepatocellular; Cell Death; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gold; Humans; Liver Neoplasms; Metal Nanoparticles; Microscopy, Electron, Transmission; Tumor Cells, Cultured	2012
Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. Cancer biotherapy & radiopharmaceuticals, 2012, Volume: 27, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated	2012
Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. Journal of hepatology, 2013, Volume: 58, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome	2013
Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis. Oncology, 2013, Volume: 84, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Prognosis; Retrospective Studies; Survival Rate	2013
Monitoring tumor response with radiolabeled nucleoside analogs in a hepatoma-bearing mouse model early after doxisome(®) treatment. Molecular imaging and biology, 2013, Volume: 15, Issue:3 Topics: Animals; Bromodeoxycytidine; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Death; Deoxycytidine; Dideoxynucleosides; Disease Models, Animal; Doxorubicin; Endocytosis; Hep G2 Cells; Humans; Immunohistochemistry; Ki-67 Antigen; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Multimodal Imaging; Polyethylene Glycols; Positron-Emission Tomography; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays	2013
Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Radiation oncology (London, England), 2013, Jan-16, Volume: 8 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Venous Thrombosis	2013
Green tea phenolic epicatechins inhibit hepatitis C virus replication via cycloxygenase-2 and attenuate virus-induced inflammation. PloS one, 2013, Volume: 8, Issue:1 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Catechin; Cell Line, Tumor; Cyclooxygenase 2; Deoxycytidine; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Humans; Inflammation; Interferon-alpha; Interleukin-1beta; Nitric Oxide Synthase Type II; Oligopeptides; RNA, Viral; Stereoisomerism; Tea; Tumor Necrosis Factor-alpha; Virus Replication	2013
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer, 2002, Jun-15, Volume: 94, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Survival Rate	2002
Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer research, 2003, Oct-01, Volume: 63, Issue:19 Topics: Adenovirus E1A Proteins; Adenoviruses, Human; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; NF-kappa B; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Transfection	2003
Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer, 2003, Dec-15, Volume: 98, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Rate; Treatment Outcome	2003
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-01, Volume: 9, Issue:16 Pt 1 Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postoperative Care; Thymidine Phosphorylase; Transplantation, Heterologous	2003
Tumor-specific gene expression using regulatory elements of the glucose transporter isoform 1 gene. Cancer gene therapy, 2004, Volume: 11, Issue:1 Topics: Animals; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Deoxycytidine; Dependovirus; Flow Cytometry; Ganciclovir; Gene Expression Regulation; Genes, Reporter; Genetic Therapy; Humans; Mice; Monosaccharide Transport Proteins; Neoplasm Transplantation; Organ Specificity; Protein Isoforms; Rats; Rats, Inbred ACI; Simplexvirus; Thymidine Kinase	2004
Screening for supra-additive effects of cytotoxic drugs and gamma irradiation in an in vitro model for hepatocellular carcinoma. Canadian journal of physiology and pharmacology, 2004, Volume: 82, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gamma Rays; Gemcitabine; Humans; Liver Neoplasms; Radiation-Sensitizing Agents; Spheroids, Cellular; Time Factors	2004
Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. Journal of cancer research and clinical oncology, 2004, Volume: 130, Issue:9 Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Interferon-alpha; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Thymidine Phosphorylase; Transplantation, Heterologous; Up-Regulation	2004
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer, 2004, Aug-01, Volume: 101, Issue:3 Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Humans; Liver Neoplasms; Male; Multivariate Analysis; Probability; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome	2004
[Low-dose gemcitabine promotes radiation-induced apoptosis of human hepatoma cell line SMMC-7721]. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2005, Volume: 25, Issue:3 Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Radiation; Radiation-Sensitizing Agents	2005
Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18F-FDG, and histologic evaluation. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46, Issue:5 Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclophosphamide; Deoxycytidine; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Liver Neoplasms; Male; Metabolic Clearance Rate; Organ Specificity; Organotechnetium Compounds; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Statistics as Topic; Tissue Distribution	2005
[Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma]. Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:8 Topics: Adenosine Triphosphate; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Postoperative Period; Remission Induction; Sensitivity and Specificity; Survival Rate	2005
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); DNA Primers; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Tomography, X-Ray Computed	2006
Hepatocellular carcinoma--Pathological complete response to oral capecitabine, megestrol and thalidomide. Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Male; Megestrol; Thalidomide; Treatment Outcome	2006
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clinical colorectal cancer, 2006, Volume: 5, Issue:5 Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms	2006
Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Hepatitis C; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs	2006
Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma. Canadian journal of physiology and pharmacology, 2006, Volume: 84, Issue:10 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cobalt Radioisotopes; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gamma Rays; Gemcitabine; Glucose Transporter Type 1; Humans; Rhenium; Topotecan	2006
Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Hepatitis B virus; HL-60 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Molecular Structure; Nucleic Acid Synthesis Inhibitors; Time Factors; Transfection; Virus Replication	2007
The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine. Molecular pharmacology, 2007, Volume: 72, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Cytosine; Deoxycytidine; Dioxolanes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Gemcitabine; Humans; Liver Neoplasms; Pancreatic Neoplasms; Phosphoglycerate Kinase; Rhabdomyosarcoma	2007
19F NMR in vivo spectroscopy reflects the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy. Magnetic resonance in medicine, 2008, Volume: 59, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Botulinum Toxins, Type A; Carcinoma, Hepatocellular; Deoxycytidine; Drug Synergism; Fluorine Radioisotopes; Gemcitabine; Magnetic Resonance Spectroscopy; Male; Mice; Neoplasms, Experimental; Peptides, Cyclic; Thalidomide	2008
[Transhepatic arterial chemoembolization with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:8 Topics: Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Quality of Life; Remission Induction; Survival Rate; Young Adult	2007
Capecitabine for treatment of advanced hepatocellular carcinoma. Hepato-gastroenterology, 2007, Volume: 54, Issue:80 Topics: Aged; Antimetabolites, Antineoplastic; Bilirubin; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Treatment Outcome	2007
Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Survival Analysis	2009
Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. World journal of gastroenterology, 2008, Apr-28, Volume: 14, Issue:16 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Patient Selection; Survival Analysis; Survivors; Treatment Outcome	2008
Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells. Journal of hepatology, 1998, Volume: 28, Issue:3 Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cladribine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Liver Neoplasms; Nucleosides; Tumor Cells, Cultured	1998
GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. International journal of oncology, 2000, Volume: 16, Issue:4 Topics: Adult; Aged; Carcinoma, Hepatocellular; CpG Islands; Deoxycytidine; DNA Methylation; DNA, Viral; Female; Glutathione S-Transferase pi; Glutathione Transferase; Hepatitis B virus; Humans; Isoenzymes; Liver Neoplasms; Male; Middle Aged; Promoter Regions, Genetic	2000
[The expression of platelet-derived endothelial cell growth factor in liver cancer]. Zhonghua yi xue za zhi, 2000, Volume: 80, Issue:11 Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Endothelial Growth Factors; Fluorouracil; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Platelet-Derived Growth Factor	2000
Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology, 2001, Volume: 60, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome	2001
Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:6 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Deoxycytidine; Half-Life; Hepatitis B; Hepatitis B virus; Hepatocytes; Humans; Liver Neoplasms; Phosphorylation; Thymidine; Tumor Cells, Cultured	2002
Repair methylation of parental DNA in synchronized cultures of Novikoff hepatoma cells. Nucleic acids research, 1975, Volume: 2, Issue:6 Topics: Animals; Bromodeoxyuridine; Carcinoma, Hepatocellular; Cell Division; Cell Line; Deoxycytidine; DNA; DNA Repair; Liver Neoplasms; Methionine; Methylation; Neoplasms, Experimental; Rats; Thymidine	1975
Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. Cancer research, 1978, Volume: 38, Issue:4 Topics: Animals; Biological Transport, Active; Carcinoma, Hepatocellular; Cells, Cultured; Cytarabine; Deoxycytidine; Deoxyribonucleotides; DNA, Neoplasm; Feedback; Hydroxyurea; Liver Neoplasms; Neoplasms, Experimental; Oxidative Phosphorylation; Rats; Thymidine	1978
The mechanism of inhibition of hepatitis B virus replication by the carbocyclic analog of 2'-deoxyguanosine. Hepatology (Baltimore, Md.), 1992, Volume: 16, Issue:1 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Line; Deoxycytidine; Deoxyguanosine; DNA Polymerase III; DNA-Directed DNA Polymerase; DNA, Viral; Hepatitis B virus; Humans; Kinetics; Liver Neoplasms; Nucleic Acid Synthesis Inhibitors; RNA, Viral; Transcription, Genetic; Virus Replication	1992
Regulation of phosphoenolpyruvate carboxykinase and tyrosine transaminase in hepatoma cell cultures. 3. Comparative studies in H35, HTC, MH1C1 and RLC cells. The Journal of cell biology, 1974, Volume: 60, Issue:1 Topics: Animals; Biological Transport; Bucladesine; Carcinoma, Hepatocellular; Cell Count; Cell Division; Cell Line; Deoxyadenosines; Deoxycytidine; Dexamethasone; Diffusion; DNA; Drug Resistance; Liver; Liver Neoplasms; Neoplasm Proteins; Phosphoenolpyruvate Carboxykinase (GTP); Rats; Time Factors; Tritium; Tyrosine Transaminase	1974
Rapid arrest of DNA synthesis by N 6 ,O 2' -dibutyryl cyclic adenosine 3',5'-monophosphate in cultured hepatoma cells. Cancer research, 1973, Volume: 33, Issue:6 Topics: Autoradiography; Butyrates; Carcinoma, Hepatocellular; Cells, Cultured; Cyclic AMP; Deoxyadenosines; Deoxycytidine; DNA, Neoplasm; Guanosine; Liver Neoplasms; Mitosis; Neoplasms, Experimental; Thymidine; Thymine Nucleotides; Tritium	1973
Letter: On the source of "minor thymine" in DNA from a Novik off rat hepatoma cell line. Journal of molecular biology, 1973, Oct-05, Volume: 79, Issue:4 Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Chromatography, Paper; Cytosine; Deamination; Deoxycytidine; DNA; Liver; Liver Neoplasms; Methotrexate; Neoplasms, Experimental; Rats; Thymidine; Thymine; Tritium	1973
A comparison of the utilization of thymine and thymidine for the synthesis of DNA-thymine in Novikoff hepatoma cells. Experimental cell research, 1974, Volume: 85, Issue:2 Topics: Alkylating Agents; Carcinoma, Hepatocellular; Cells, Cultured; Deoxyadenosines; Deoxycytidine; Deoxyribonucleosides; Deoxyuridine; DNA, Neoplasm; Guanosine; Kinetics; Liver Neoplasms; Mesylates; Neoplasms, Experimental; Thymidine; Thymine; Tritium	1974